Biotechnology stocks are a subset of a much broader sector, healthcare. Where most investors look to find opportunities with the likes of Pfizer of Johnson & Johnson, others look for early-stage, start-ups.
Though there’s more risk involved, there could also be potential for even bigger payouts. Just take a look at some of the top biotech breakouts we’ve already seen this year.
It wasn’t based on massive buyouts or huge commercial revenues but early data that triggered these big moves. There are countless examples of pre-clinical and clinical-stage companies hitting it big after reporting meaningful data. And it’s usually the early onlookers who may have the upper hand at capitalizing.
Small-Cap Biotech Stocks To Watch:
GT Biopharma (GTBP)
Market Cap: $9.591M
Early, clinical-stage companies like GT Biopharma (GTBP) present a number of value propositions for investors. So far, GT Biopharma has come up favorably with strong trial results on more than just one of its therapies. The most recent focus for the company has been on its TriKE™ Technology and more specifically, its HIV-TriKE™ therapy.
The company caught the market’s attention earlier this month after it reported the results of its poster presentations. This was at the 18th meeting of the Society for Natural Immunity in Luxembourg. What was exactly reported and why are eyebrows raising? In his own words, Anthony Cataldo, the Chairman and Chief Executive Officer of GT Biopharma said,
But this is just one aspect of the GT Biopharma story. The company also reported that notified FDA that it was commencing enrollment in its first-in-human GTB-3550 Phase I/II clinical trial. GTB-3550 (OXS-3550) is the Company’s first Tri-specific NK cell Engager (TriKE™) product candidate being initially developed for the treatment of acute myeloid leukemia. With an upcoming trial, it’s likely a potential focus for anyone looking at early stage biotech stocks.
Ritter Pharmaceuticals, Inc. (RTTR)
Market Cap: $3.507M
Similar to how favorable investors can react to positive data, negative data can result in the opposite. Ritter Pharmaceuticals (RTTR) has fallen victim to this instance. But recent news has sparked rejuvenated interest in the biotech stock. First, what happened?
Back in mid-September, Ritter reported trial results. Its Phase 3 clinical trial of RP-G28 failed to “demonstrate statistical significance.” Shares plummeted from $1.13 to lows of $0.23. This week the company announced that it has engaged A.G.P./Alliance Global Partners as financial advisor to explore and evaluate strategic alternatives to enhance shareholder value.
This includes, “Potential strategic alternatives that may be explored or evaluated by the Company as part of this process include an acquisition, merger, reverse merger, other business combination, sale of assets, licensing or other strategic transactions involving the Company.” With this news, RTTR stock price hiked to highs of over $0.40 and closed above $0.35 to start the week.
Cancer Genetics Inc. (CGIX)
Market Cap: $9.722 M
It’s been a tough go this year for Cancer Genetics (CGIX) but recent trading activity may suggest something different. After being slammed to 52-week lows of $0.085, CGIX stock price has bounced back by more than 75%. However, there hasn’t been much on the news-front.
Earlier this year, Interpace Diagnostics purchased the Biopharma Services unit of the Cancer Genetics. For most of the second half of the year, management has been working on improving its financial position. It has divested certain units while also selling off pieces (as noted prior).
“With these asset sales now completed, we believe the Company is in a good position to explore further strategic initiatives as well as to grow the remaining Discovery Services business,” said John A. Roberts, Chief Executive Officer of Cancer Genetics.
Disclaimer: Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP). Click here For Full Disclaimer.